Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sigma-Aldrich To Acquire BioReliance
by Marc S. Reisch
January 16, 2012
| A version of this story appeared in
Volume 90, Issue 3
Sigma-Aldrich has signed an agreement to acquire BioReliance Holdings, a biopharmaceutical testing services firm, from Avista Capital Partners for $350 million. The acquisition, expected to close by the end of March, will extend Sigma’s reach beyond its traditional chemical supply business into services that include biologic, specialized toxicology, and animal health testing for pharmaceutical, diagnostic, and other customers. BioReliance had sales of $110 million in 2011. It employs more than 650 people at its headquarters in Rockville, Md., and in Glasgow and Stirling, Scotland.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X